Globus Medical, Inc. (NYSE:GMED) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Globus Medical, Inc. (NYSE:GMED) have been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $99.46.

Several equities analysts recently issued reports on GMED shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. BMO Capital Markets began coverage on Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price target for the company. Truist Financial dropped their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Finally, UBS Group assumed coverage on Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective on the stock.

Insider Activity

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James R. Tobin sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Paradigm Capital Management Inc. NY bought a new position in shares of Globus Medical in the 2nd quarter valued at about $70,042,000. American Capital Management Inc. acquired a new position in shares of Globus Medical during the 2nd quarter worth approximately $51,599,000. Hawk Ridge Capital Management LP bought a new stake in shares of Globus Medical during the 1st quarter worth approximately $43,078,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

GMED opened at $81.12 on Friday. The company has a market capitalization of $10.89 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.31 and a beta of 0.96. The firm’s fifty day moving average price is $77.90 and its two-hundred day moving average price is $83.63. Globus Medical has a fifty-two week low of $59.51 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. During the same period in the previous year, the business earned $0.86 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts expect that Globus Medical will post 4.99 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.